Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated ...
With most myelofibrosis patients becoming anemic over time, Ojjaara's approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK's commitment ...
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated with ...